Zobrazeno 1 - 10
of 197
pro vyhledávání: '"M. van Eggermond"'
Publikováno v:
ISPRS Annals of the Photogrammetry, Remote Sensing and Spatial Information Sciences, Vol V-4-2021, Pp 225-232 (2021)
With this paper, we present a novel approach for efficiently creating reality-based, high-fidelity urban 3D models for interactive VR cycling simulations. The foundation of these 3D models is accurately georeferenced street-level imagery, which can b
Externí odkaz:
https://doaj.org/article/ec2e28196a2b4260a257910ae65fc93a
Autor:
Nicola S. Russell, Inge M. Krul, Anna M. van Eggermond, Berthe M.P. Aleman, Rosie Cooke, Susanne Kuiper, Steven D. Allen, Matthew G. Wallis, Damien Llanas, Ibrahima Diallo, Florent de Vathaire, Susan A. Smith, Michael Hauptmann, Annegien Broeks, Anthony J. Swerdlow, Flora E. Van Leeuwen
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 7, Iss , Pp 20-27 (2017)
Background: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has now been robustly established. In order to estimate the doseâresponse relationship more accurately, and to aid clinical decision making, a retrospect
Externí odkaz:
https://doaj.org/article/20cd8850c0b447a780edddb7c58bef99
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Josée M. Zijlstra, Otto Visser, Gustaaf W. van Imhoff, Judith M. Roesink, Michael Schaapveld, Monique E. van Leerdam, Philip Poortmans, Augustinus D.G. Krol, Petur Snaebjornsson, Pieternella J. Lugtenburg, Cecile P.M. Janus, Richard W.M. van der Maazen, Max Beijert, Berthe M.P. Aleman, Lisanne S. Rigter, Flora E. van Leeuwen, Anna M. van Eggermond
Publikováno v:
Cancer Medicine, 8(1), 190-199
Cancer Medicine, 8, 190-199
Cancer Medicine, 8(1), 190-199. John Wiley and Sons Ltd
Cancer Medicine, 8(1), 190-199. John Wiley & Sons Ltd.
Cancer Medicine
Cancer Medicine, 8, 1, pp. 190-199
Cancer medicine, 8(1), 190-199. Wiley
Cancer Medicine, 8(1), 190. John Wiley and Sons Ltd
Rigter, L S, Schaapveld, M, Janus, C P M, Krol, A D G, van der Maazen, R W M, Roesink, J, Zijlstra, J M, van Imhoff, G W, Poortmans, P M P, Beijert, M, Lugtenburg, P J, Visser, O, Snaebjornsson, P, van Eggermond, A M, Aleman, B M P, van Leeuwen, F E & van Leerdam, M E 2019, ' Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer ', Cancer Medicine, vol. 8, no. 1, pp. 190-199 . https://doi.org/10.1002/cam4.1922
Cancer Medicine, 8, 190-199
Cancer Medicine, 8(1), 190-199. John Wiley and Sons Ltd
Cancer Medicine, 8(1), 190-199. John Wiley & Sons Ltd.
Cancer Medicine
Cancer Medicine, 8, 1, pp. 190-199
Cancer medicine, 8(1), 190-199. Wiley
Cancer Medicine, 8(1), 190. John Wiley and Sons Ltd
Rigter, L S, Schaapveld, M, Janus, C P M, Krol, A D G, van der Maazen, R W M, Roesink, J, Zijlstra, J M, van Imhoff, G W, Poortmans, P M P, Beijert, M, Lugtenburg, P J, Visser, O, Snaebjornsson, P, van Eggermond, A M, Aleman, B M P, van Leeuwen, F E & van Leerdam, M E 2019, ' Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer ', Cancer Medicine, vol. 8, no. 1, pp. 190-199 . https://doi.org/10.1002/cam4.1922
Contains fulltext : 203188.pdf (Publisher’s version ) (Open Access) BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and dev
Autor:
Richard W.M. van der Maazen, Berthe M.P. Aleman, Karijn M.S. Verschueren, Max Beijert, Josee M. Zijlstra, Jan de Boer, Marten R. Nijziel, Dick Johan van Spronsen, Flora E. van Leeuwen, Eefke Petersen, Anna M. van Eggermond, Simone de Vries, Gustaaf W. van Imhoff, Wouter J. Plattel, Cecile P.M. Janus, Pieternella J. Lugtenburg, Judith M. Roesink, Leontien C. M. Kremer, Augustinus D.G. Krol, Laurien A. Daniëls, Michael Schaapveld
Publikováno v:
JNCI Journal of the National Cancer Institute
Journal of the National Cancer Institute, 113, 6, pp. 760-769
JNCI: Journal of the National Cancer Institute, 113(6), 760-769. OXFORD UNIV PRESS INC
Journal of the National Cancer Institute, 113(6), 760-769. Oxford University Press
Journal of the National Cancer Institute, 113, 760-769
Journal of the National Cancer Institute, 113, 6, pp. 760-769
JNCI: Journal of the National Cancer Institute, 113(6), 760-769. OXFORD UNIV PRESS INC
Journal of the National Cancer Institute, 113(6), 760-769. Oxford University Press
Journal of the National Cancer Institute, 113, 760-769
Background Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients. Methods This multicenter cohort included 4919 HL patients, treated before age 51 years between 19
Autor:
Rosie Cooke, Michael Hauptmann, Anna M. van Eggermond, Matthew G. Wallis, Ibrahima Diallo, Steven D. Allen, Annegien Broeks, Florent de Vathaire, Berthe M.P. Aleman, Flora E. van Leeuwen, Susan A. Smith, Anthony J. Swerdlow, Damien Llanas, Inge M. Krul, Susanne Kuiper, Nicola S. Russell
Publikováno v:
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 7, Iss, Pp 20-27 (2017)
Clinical and Translational Radiation Oncology, Vol 7, Iss, Pp 20-27 (2017)
Background: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has now been robustly established. In order to estimate the doseâresponse relationship more accurately, and to aid clinical decision making, a retrospect
Autor:
Flora E. van Leeuwen, Jan de Boer, Augustinus D.G. Krol, Marieke W. J. Louwman, Berthe M.P. Aleman, Anna M. van Eggermond, Pieternella J. Lugtenburg, Judith M. Roesink, John M. M. Raemaekers, Josée M. Zijlstra, Michael Schaapveld, Leontien C. M. Kremer
Publikováno v:
van Eggermond, A M, Schaapveld, M, Lugtenburg, P J, Krol, A D G, de Boer, J P, Zijlstra, J M, Raemaekers, J M M, Kremer, L C M, Roesink, J M, Louwman, M W J, Aleman, B M P & van Leeuwen, F E 2014, ' Risk of multiple primary malignancies following treatment of Hodgkin lymphoma ', Blood, vol. 124, no. 3, pp. 319-327 . https://doi.org/10.1182/blood-2013-10-532184
Blood, 124(3), 319-327. American Society of Hematology
Blood, 124(3), 319-327
Blood, 124, 3, pp. 319-327; quiz 466
Blood, 124, 319-327; quiz 466
Blood, 124(3), 319-327. American Society of Hematology
Blood, 124(3), 319-327
Blood, 124, 3, pp. 319-327; quiz 466
Blood, 124, 319-327; quiz 466
Contains fulltext : 137565.pdf (Publisher’s version ) (Closed access) We assessed risk, localization, and timing of third malignancies in Hodgkin lymphoma (HL) survivors. In a cohort of 3122 5-year HL survivors diagnosed before the age of 51 years
Autor:
Max Beijert, Richard W.M. van der Maazen, Michael Schaapveld, J.M. Zijlstra, B.M.P. Aleman, Lisanne S. Rigter, Augustinus D.G. Krol, Monique E. van Leerdam, P. Poortmans, P. J. Lugtenburg, Judith M. Roesink, Gustaaf W. van Imhoff, F.E. van Leeuwen, Petur Snaebjornsson, Anna M. van Eggermond, Otto Visser, C.P.M. Janus
Publikováno v:
Hematological Oncology. 35:176-177
Autor:
Marieke W. J. Louwman, Richard W.M. van der Maazen, Pieternella J. Lugtenburg, Cecile P.M. Janus, Max Beijert, Josée M. Zijlstra, Otto Visser, Philip Poortmans, Flora E. van Leeuwen, Judith M. Roesink, Marnix L.M. Lybeert, Michael Schaapveld, Inge M. Krul, Augustinus D.G. Krol, Ina Mulder, Jan de Boer, Gustaaf W. van Imhoff, Eefke Petersen, Anna M. van Eggermond, Berthe M.P. Aleman, John M. M. Raemaekers
Publikováno v:
The New England Journal of Medicine, 373, 2499-511
New England Journal of Medicine, 373(26), 2499-2511. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 373(26), 2499-2511. Massachussetts Medical Society
Schaapveld, M, Aleman, B M P, van Eggermond, A M, Janus, C P M, Krol, A D G, van der Maazen, R W M, Roesink, J, Raemaekers, J M M, de Boer, J P, Zijlstra, J M, van Imhoff, G W, Petersen, E J, Poortmans, P M P, Beijert, M, Lybeert, M L, Mulder, I, Visser, O, Louwman, M W J, Krul, I M, Lugtenburg, P J & van Leeuwen, F E 2015, ' Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma ', New England Journal of Medicine, vol. 373, no. 26, pp. 2499-2511 . https://doi.org/10.1056/NEJMoa1505949
The New England Journal of Medicine, 373, 26, pp. 2499-511
New England Journal of Medicine, 373(26), 2499-2511
New England Journal of Medicine, 373(26), 2499-2511. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 373(26), 2499-2511. Massachussetts Medical Society
Schaapveld, M, Aleman, B M P, van Eggermond, A M, Janus, C P M, Krol, A D G, van der Maazen, R W M, Roesink, J, Raemaekers, J M M, de Boer, J P, Zijlstra, J M, van Imhoff, G W, Petersen, E J, Poortmans, P M P, Beijert, M, Lybeert, M L, Mulder, I, Visser, O, Louwman, M W J, Krul, I M, Lugtenburg, P J & van Leeuwen, F E 2015, ' Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma ', New England Journal of Medicine, vol. 373, no. 26, pp. 2499-2511 . https://doi.org/10.1056/NEJMoa1505949
The New England Journal of Medicine, 373, 26, pp. 2499-511
New England Journal of Medicine, 373(26), 2499-2511
Contains fulltext : 152700.pdf (Publisher’s version ) (Open Access) BACKGROUND: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265205737ebd8ed0a8750c9c7d19c944
http://hdl.handle.net/2066/152700
http://hdl.handle.net/2066/152700
Autor:
Pieternella J. Lugtenburg, Monique E. van Leerdam, Max Beijert, Richard W.M. van der Maazen, Petur Snaebjornsson, Augustinus D.G. Krol, Philip Poortmans, Michael Schaapveld, Josée M. Zijlstra, Otto Visser, Gustaaf W. van Imhoff, Lisanne S. Rigter, Cecile P.M. Janus, Berthe M.P. Aleman, Judith M. Roesink, Flora E. van Leeuwen, Anna M. van Eggermond
Publikováno v:
Journal of Clinical Oncology. 35:40-40
40 Background: The risk of developing gastrointestinal (GI) cancer is increased in Hodgkin lymphoma survivors. This study aims to compare overall survival of GI cancer in Hodgkin lymphoma survivors with survival of first primary GI cancer patients. M